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Venlafaxine-Induced Delirium
Dear Editor:
Venlafaxine has been associated with delirium but, typically, only in the context of serotonin syndrome. We are aware of only a single report of isolated delirium attributable to venlafaxine (1) . Venlafaxine inhibits serotonin and norepinephrine reuptake. It is also a weak inhibitor of dopamine reuptake. Interestingly, venlafaxine has one of the highest incidences of precipitating serotonin syndrome and has even been shown to elicit serotonin syndrome on its own (2, 3) . We report a case of isolated delirium in an individual receiving venlafaxine and ibuprofen.
Case Report
Ms A, aged 46 years, presented to the emergency department disoriented, with auditory hallucinations, loose associations, irritability, and a disorganized thought process. Collateral history revealed that the onset of symptoms developed suddenly, in the previous 36 hours. Her medical history was noncontributory. Her psychiatric history included dysthymia and alcohol dependence, although she claimed to have abstained from alcohol for the past 5 years. She had a long history of ibuprofen consumption (600 mg orally 3 times daily) and felt that this helped her with irritability and reduced her craving for nicotine. Approximately 4 weeks prior to presenting, she was started on venlafaxine 37.5 mg orally each morning and 75 mg orally at bedtime, for depression. She was given a sample of venlafaxine and admitted to taking more than the recommended amount, owing to an unclear understanding of the prescribed dosage.
Other causes of delirium were investigated through examination and laboratory values. Her initial blood pressure was 170/94, with a subsequent recording of 140/79. The rest of her physical and neurological exam was within normal limits. Blood alcohol level was undetected, and other laboratory values, including thyroid-stimulating hormone (TSH), complete blood count (CBC), and a basic metabolic panel, were essentially normal. Regrettably, a serum venlafaxine level was not drawn.
Ms A was admitted to the psychiatric unit and started on venlafaxine (extended release) 150 mg daily and olanzapine 5 mg daily at bedtime. Two days after admission, the patient's delirium resolved and she was discharged on venlafaxine (extended release) 150 mg daily. Discontinuation of ibuprofen was advised. Follow-up 6 weeks later revealed no residual effects of the delirium.
The delirium illustrated in Ms A was most likely produced by high levels of venlafaxine. To our knowledge, there is no literature to support the idea that ibuprofen interacts with venlafaxine; however, it is plausible, considering that both are metabolized by the liver. Whether this patient's delirium was on the continuum of serotonin syndrome, even though she clearly did not demonstrate autonomic instability or neuromuscular changes, remains unresolved. When high levels of venlafaxine are suspected, a high index of suspicion for serotonin syndrome and delirium is warranted. Owing to venlafaxine's increased popularity, we encourage further investigation of the therapeutic index and potential drug interactions of venlafaxine.
Christopher Howe, Medical Student; Sajid Ravasia, MD Fargo, North Dakota
New Dosage-Reduction Regime to Avoid Paroxetine Discontinuation Syndrome
The serotonin reuptake inhibitor (SRI) discontinuation syndrome appears soon after an SRI or venlafaxine is stopped or decreased. Its symptoms are dizziness, instability, paraesthesia, nausea, fatigue, chills, anxiety, and insomnia (1), which usually develop within the first 24 hours after dosage reduction. With venlafaxine, symptoms can sometimes occur within the first 6 hours. It is unclear whether this syndrome should be thought of in terms of abstinence, similar to that appearing after withdrawal of other medication (that is, benzodiazepines) or in terms of withdrawal from toxic substances (for example, heroin). This distinction is relevant on clinical and legal grounds, since it could be asserted that a patient who develops the syndrome has become addicted to the drug.
More often reported after withdrawal of paroxetine, the syndrome has raised concern inasmuch as it can become difficult to stop a treatment. Where no controlledrelease or liquid forms are marketed, tapering as slowly as possible is the only way to prevent the syndrome; in some cases, currently unavailable dosage forms could be necessary. It is also mandatory to completely inform patients regarding the characteristics of the problem.
We previously proposed a regime to discontinue paroxetine that, even though helpful in diminishing syndrome incidence, did not prove as successful as we had expected (2) . More recently, we have tried other strategies that proved more effective, although still not always successful. Therefore, we feel that an even slower dosage reduction should be attempted. If we are to achieve this in countries such as Spain, where only 20mg tablets are available, manufacturers must produce new forms properly grooved to allow smaller dosages.
Our current method of discontinuing paroxetine in patients on 20-mg daily dosage is to taper it down every 20 days, as follows: Even though it is not coherent with paroxetine's pharmacocynetic and pharmacodynamic properties, this approach has proved helpful. Nevertheless, it is not always effective, and we are therefore planning to taper off every 30 days instead. However, in the absence of controlled-release or liquid forms, 2.5-mg decrements would be more appropriate. 
Risperidone-Induced Galactorrhoea: A Case Series
Although galactorrhea induced by atypical antipsychotics, particularly risperidone, has been reported (1-5), the clinical course of this adverse effects has not been adequately described. This report addresses the issue.
Case Report 1
A 31-year-old woman suffering her fourth affective episode (specifically, amitriptyline-precipitated mania) was started on risperidone 4 mg daily, along with ongoing carbamazepine 800 mg daily and lithium 900 mg daily. During the seventh week of treatment, she developed galactorrhea without other features of hyperprolactinemia. At that time, because she was found to have hypothyroidism (triiodothyronine [T 3 ], 30.0 µg/dl; thyroxine [T 4 ], 2.5µg/dl; thyroidstimulating hormone [TSH], 3.9 µU/ml), thyroxine 25µg daily was added. Simultaneously, trifluoperazine (5 mg daily) was started in place of risperidone, with which her galactorrhea and manic symptoms disappeared over 2 months.
Case Report 2
A 26-year-old woman suffering from major depression with catatonia received 7 doses of electroconvulsive therapy and then began haloperidol 5 mg daily and fluoxetine 20 mg daily. However, haloperidol was later discontinued, owing to extrapyramidal symptoms (EPS), and she began taking risperidone 2 mg daily and trihexyphenidyl 2 mg daily. Her depression and EPS improved after 3 weeks, but after 1 month of treatment, she developed galactorrhea without other hyperprolactinemic features. Her thyroid profile was normal. Consequently, her risperidone was discontinued, and within 2 weeks and while on fluoxetine, her galactorrhea remitted.
Case Report 3
A 24-year-old woman was treated with sertraline 50 mg daily and risperidone 3 mg daily for major depression with psychotic features and comorbid obsessive-compulsive disorder (OCD). During week 3, she developed galactorrhea without other hyperprolactinemic features; consequently, risperidone was stopped. She was euthyroid. Despite improvement in her symptoms, except for galactorrhea, she discontinued medications during week 6 of therapy. This led to exacerbated depressive, psychotic, and OC symptoms, and her galactorrhea persisted. She was then given sertraline 100 mg daily, along with chlorpromazine 100 mg daily, and within 2 weeks, despite only partial improvement in her psychopathology, her galactorrhea disappeared.
Case Report 4
A 34-year-old woman was taking carbamazepine 800 mg daily and haloperidol 5 mg daily to treat bipolar affective disorder diagnosed according to DSM-IV criteria. Because she developed signs of tardive dyskinesia, her haloperidol was stopped and risperidone 4 mg daily was started. After 3 months of treatment, she gradually developed amenorrhea and, 5 months later, galactorrhea. Having had a normal thyroid profile and prolactin level (that is, 1.006 ng/ml, where a normal level is < 20.0 ng/ml), she had no other hyperprolactinemic features. Owing to the distressful galactorrhea, risperidone was discontinued, and both
